statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ClearPoint Neuro, Inc. (NASDAQ: CLPT) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation...

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ClearPoint Neuro, Inc. (NASDAQ: CLPT)

This is a signal that CLPT's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

ClearPoint Neuro (CLPT, $6.73) Stochastic Oscillator left the oversold zone on April 01, 2024

ClearPoint Neuro (CLPT, $6.81) Stochastic Oscillator left the oversold zone on March 28, 2024

This indicator may be signaling that CLPT's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

ClearPoint Neuro (CLPT, $6.69) entered Downtrend as Momentum indicator drops below 0 level on Mar 27, 2024

ClearPoint Neuro (NASDAQ:CLPT  Get Free Report) and Nephros (NASDAQ:NEPH  Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two...

ClearPoint Neuro (NASDAQ:CLPT) versus Nephros (NASDAQ:NEPH) Critical Survey

This price move could indicate a change in the trend, and may be a sell signal for investors...

ClearPoint Neuro (CLPT, $6.98) price exceeded its 50-day Moving Average on March 19, 2024

If Approved, Upstaza Would be the First Disease-Modifying Treatment for AADC Deficiency in the United States
 ClearPoint Neuro

 ClearPoint Neuro Navigation Platform for Drug...

ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza as a Treatment for AADC Deficiency

ClearPoint Neuro (CLPT, $7.06) price exceeded its 50-day Moving Average on March 18, 2024

This is a Bullish indicator signaling CLPT's price could rise from here. Traders may explore going long the stock or buying call options...

ClearPoint Neuro (CLPT, $7.24) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 14, 2024

Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The firm conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform consists of the ClearPoint system and ClearTrace system. The company was founded by Paul A. Bottomley on March 12, 1998 and is headquartered in Solana Beach, CA.

Watchers	2,524
52-Wk Low	$4.05
52-Wk High	$8.68

Volume	78,994.00
52-Wk High	$8.68
52-Wk Low	$4.05

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.18	--	--	N/A
Q1'24	-$0.19	-$0.16	15.79%	BEAT
Q4'23	-$0.20	-$0.18	11.48%	BEAT
Q3'23	-$0.25	-$0.20	20.00%	BEAT
Q2'23	-$0.19	-$0.29	-52.63%	MISSED

CLPT ClearPoint Neuro Inc

About

Feed

News

Sentiment

Earnings

Fundamentals